IHC News and Research

RSS

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from their Huntington’s disease program at the 2009 World Congress on Huntington’s Disease held September 12-15, 2009 in Vancouver, British Columbia.

15 Sep 2009

IAC picks Axway's SecureTransport solution to protect health and billing information during transit

Looking to better safeguard and monitor private patient data in transit, Insurers Administrative Corporation (IAC) chose Axway’s SecureTransport™ solution with Synchrony™ Sentinel. IAC chose Axway SecureTransport to protect sensitive health and billing information between insurance companies and medical facilities. Axway’s Sentinel will help IAC gain unprecedented visibility across all file transfers.

15 Sep 2009

Fifth annual Pathology Visions conference to showcase digital pathology technology and its healthcare applications

The newly formed Digital Pathology Association (DPA), a non-profit organization committed to the advancement of digital pathology applications in healthcare, invites interested pathology professionals to join them for the fifth annual Pathology Visions conference, to be held September 13-15 in San Diego, CA, at the Marriott Hotel and Marina.

31 Aug 2009

IVD labeled staining reagents for manual and automated staining platforms from DBS

Diagnostic Biosystems (DBS), a specialty immunohistochemistry (IHC) reagent company, announces the availability of products for clinical use in the US.

27 Aug 2009

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

Despite recent advances in diagnosis and treatment, the prognosis of patients with biliary tract cancer is still poor. Elucidating the biological characteristics of these carcinomas has become necessary to improve the prognosis of patients and to devise better treatment strategies. A recent study report that invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in the progression of biliary tract cancer.

26 Aug 2009

FDA clears Aperio Technologies to market breast tissue image analysis application

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the IHC HER2 Breast Tissue Image Analysis application, available through its patented digital pathology platform.

25 Aug 2009

New software programs improve the cancer biomarker identification process

caCORRECT and omniBioMarker programs earn silver-level compatibility certification from NIH/National Cancer Institute's cancer Bioinformatics Grid

19 Aug 2009

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

OSI Pharmaceuticals, Inc. has announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy.

2 Aug 2009

Loss of stromal protein major new prognostic factor in patients with breast cancer

Reporting online in the American Journal of Pathology, researchers from the Kimmel Cancer Center at Jefferson have implicated the loss of a stromal protein called caveolin-1 as a major new prognostic factor in patients with breast cancer, predicting early disease recurrence, metastasis and breast cancer patient survival.

6 May 2009

New gene called DEAR1 may be a breast cancer diagnostic marker

In a research article published in this week's PLoS Medicine, Ann Killary (from the University of Texas M. D. Anderson Cancer Center) and colleagues describe a new gene called DEAR1 that is genetically altered by mutation and deletion in breast tumors, and that may provide a new breast cancer prognostic marker.

4 May 2009

Molecular profiling helps cancer patients survive

Cancer patients can survive longer under treatments based on their individual genetic profiles, according to a nationwide study released jointly today by Phoenix-area healthcare organizations.

20 Apr 2009

A potential therapeutic target for gastric cancer

Gastric cancer (GC) is the fourth most common malignancy and the second most frequent cause of cancer-related death in the world.

20 Apr 2009

Do patients at risk for B-cell malignancy need antiviral treatment?

Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.

15 Apr 2009

New molecular marker of gastric cancer

Gastric cancer (GC) is one of the most common malignancies in the world with a high incidence and death rate.

30 Mar 2009

Collagen VI protects brain cells against amyloid-beta proteins

Scientists from the Gladstone Institute of Neurological Disease (GIND), UCSF, and Stanford have discovered that a certain type of collagen, collagen VI, protects brain cells against amyloid-beta proteins, which are widely thought to cause Alzheimer's disease (AD).

5 Jan 2009

PreMD files provisional patent application for new method of quantifying cancer biomarkers

Predictive medicine company PreMD Inc. has announced that it has filed a provisional patent application that describes a new simplified method of quantifying immunohistochemical staining of biomarkers. The provisional patent application was filed with the United States Patent and Trademark office.

11 Dec 2008

IHC News and Research

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

IAC picks Axway's SecureTransport solution to protect health and billing information during transit

Fifth annual Pathology Visions conference to showcase digital pathology technology and its healthcare applications

IVD labeled staining reagents for manual and automated staining platforms from DBS

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

FDA clears Aperio Technologies to market breast tissue image analysis application

New software programs improve the cancer biomarker identification process

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

Loss of stromal protein major new prognostic factor in patients with breast cancer

New gene called DEAR1 may be a breast cancer diagnostic marker

Molecular profiling helps cancer patients survive

A potential therapeutic target for gastric cancer

Do patients at risk for B-cell malignancy need antiviral treatment?

New molecular marker of gastric cancer

Collagen VI protects brain cells against amyloid-beta proteins

PreMD files provisional patent application for new method of quantifying cancer biomarkers

Study explains fundamental process of tumor growth

Study helps explain how tumor cells rapidly grow and proliferate

A new significance of LVD and angiogenic MVD is identified in human primary SCRC

Trop-2 new target for anti-tumour therapy in cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News